The global insulin delivery pens market size is predicted to increase from USD 25,578 million in 2025 and is anticipated to ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global ...

As the diabetes and weight loss market booms, more collaboration between pharma and medtech could help patients get the most ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Receiving FDA clearance would allow Medtronic to pair its pumps with a glucose monitor being developed for the company by ...

Chennai: Every Saturday, six specialists at the newly opened Teen Clinic at Rajiv Gandhi Govt General Hospital attend to ...

Abu Dhabi: In a historic collaboration that could redefine both space medicine and diabetes care, a UAE study led by Abu ...

Indian diabetic population on Human Mixtard concerned on changes in insulin therapy: Nandita Vijayasimha, Bengaluru Thursday, April 24, 2025, 08:00 Hrs [IST] India’s diabetic po ...

Novo Nordisk’s insulin brand Mixtard will continue to be available in vials, the Danish healthcare company clarified, even as ...